Apollon Formulations

Apollon Formularies is a biopharmaceutical company specializing in the development of innovative cancer and chronic pain treatments using medical cannabis and medicinal mushroom formulations. Headquartered in the UK with primary operations in Jamaica, the company utilizes a federally licensed facility to conduct research, development, and patient care at its International Cancer and Chronic Pain Institute. Their proprietary approach integrates artificial intelligence to identify and optimize combinations of cannabinoids and functional mushrooms, which have shown high efficacy in killing various cancer cell lines, including HER2+ and triple-negative breast cancer, in pre-clinical studies. Following its acquisition by Sproutly Canada Inc. in late 2023 and subsequent delisting from the Aquis Stock Exchange in 2024, the company continues to advance its portfolio of natural biologic therapeutics.